AU Patent

AU2021296786A1 — Methods and compositions for treating hemophilia

Assigned to Genzyme Corp · Expires 2023-02-23 · 3y expired

What this patent protects

The present disclosure provides using a double-stranded oligonucleotide compound as a novel therapy to improve the quality of life and joint function of patients with hemophilia A and hemophilia B.

USPTO Abstract

The present disclosure provides using a double-stranded oligonucleotide compound as a novel therapy to improve the quality of life and joint function of patients with hemophilia A and hemophilia B.

Drugs covered by this patent

Patent Metadata

Patent number: AU2021296786A1
Jurisdiction: AU
Classification: —
Expires: 2023-02-23
Drug substance claim: No
Drug product claim: No
Assignee: Genzyme Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.